Mankind Pharma Q1 FY27 Earnings Call Transcript Released
Mankind Pharma reported Q1 FY27 revenue of ₹4,031 crore, up 13% YoY. EBITDA margin improved to 26.3%. Domestic revenue grew 11% to ₹3,180 crore. International business grew 29% to ₹605 crore. Profit after tax increased 29.1% to ₹574 crore.
The announcement provides detailed financial results and strategic updates, which are material information for investors and analysts.
The company reported strong year-on-year growth in revenue, EBITDA, and profit after tax, with improvements in key business segments and margins.
Mankind Pharma Limited has released the transcript of its Investor Conference Call for the first quarter of FY27, which was held on Thursday, July 30, 2026. The company reported an overall revenue increase of 13% year-on-year to ₹4,031 crore, with EBITDA improving by 250 basis points to 26.3%.
Domestic revenue, excluding Consumer Healthcare, grew by 11% year-on-year to ₹3,180 crore, driven by double-digit growth in the base business and strong momentum in chronic and BSV specialty segments. Secondary sales, as per IQVIA, grew 12.7%, with healthy volume growth of 4.7%. The company aims to increase its chronic share to 50% in the medium term and has launched a new division, Vistar, to scale up lesser-focused brands.
The Consumer Healthcare business delivered ₹246 crore in revenue, with market share gains in key brands like Manforce and Preganews. The company has partnered with Denovo Science for an AI-led drug discovery program.
Internationally, revenue grew 29% year-on-year to ₹605 crore. Gross margins increased to 72.8%, and reported EBITDA margin improved to 26.3%. Profit after tax grew 29.1% year-on-year to ₹574 crore, with PAT margin improving to 14.2%. The company remains on track to repay acquisition-related debt by FY28.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.